按HIV状态评估香港男男性行为者接种九价HPV疫苗的成本效果
本研究用马尔可夫模型模拟香港10万名男男性行为者(MSM)按年龄组和HIV状态分层接种九价HPV疫苗的成本效果,结果显示所有接种策略的增量成本效果比均低于 willingness-to-pay 阈值(每获得一个质量调整生命年 USD 50,696)或具有成本节约,其中接种所有≥12岁MSM预防肛门生殖器疣(52.5%)和肛门癌(70.4%)最多。
要点
- 接种所有≥12岁MSM预防肛门生殖器疣52.5%、肛门癌70.4%,健康收益最大。
- 所有MSM接种策略的ICER均低于每QALY USD 50,696的支付意愿阈值或具有成本节约。
- 概率敏感性分析中,≥12岁MSM接种策略始终显示高概率具有成本效果。
核心结论
- 研究结果支持在香港MSM中实施九价HPV疫苗接种,接种所有≥12岁MSM提供最大的健康和经济收益。
研究设计与样本
- 研究建立马尔可夫模型模拟香港10万名MSM的HPV感染自然史及进展为肛门生殖器疣和肛门癌的过程,按四个年龄组(12-18、19-27、28-45、>45岁)和HIV状态(阳性或阴性)分层。
- 研究采用10年时间跨度,从医疗服务提供者视角分析,主要结局为每获得一个质量调整生命年(QALY)的增量成本效果比(ICER),并进行单因素和概率敏感性分析。
主要发现
- 实施九价HPV疫苗接种策略后,模型模拟的肛门癌和肛门生殖器疣发病率显著降低。
- 接种所有≥12岁MSM预防肛门生殖器疣52.5%和肛门癌70.4%,为所有策略中预防病例最多者。
- 所有评估的MSM接种策略的ICER均低于支付意愿阈值每QALY USD 50,696(香港人均GDP的一次性值)或具有成本节约,表明所有九价HPV接种策略均具有成本效果。
- 概率敏感性分析中,≥12岁MSM接种策略始终显示高概率具有成本效果。
- 当九价HPV疫苗成本降低或时间跨度延长时,≥12岁MSM接种策略的ICER进一步下降,使该策略更具成本效果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human papillomavirus (HPV) is the most common sexually transmitted infection and a leading cause of anal cancer and genital warts, particularly among men who have sex with men (MSM). In Hong Kong, HPV vaccination is currently only offered to school-aged girls, despite the high burden of HPV-related diseases among MSM, especially those living with HIV. Existing cost-effectiveness evaluations of HPV vaccination in Hong Kong primarily focus on female-only strategies and heterosexual men without accounting for differences in HPV infection risks among MSM. In contrast, countries such as the United Kingdom initially implemented free HPV vaccination for MSM through sexual health clinics, followed by an expansion of the programme to include adolescent boys. This provides a potentially useful model for Hong Kong to consider. This study aimed to evaluate the cost-effectiveness of implementing 9-valent HPV (9vHPV) vaccination strategies among HIV-positive and HIV-negative MSM in Hong Kong. METHODS: We developed a Markov model to simulate the natural history of HPV infection and progression to genital warts, and anal cancer in a cohort of 100,000 MSM in Hong Kong, stratified by four age groups (12-18, 19-27, 28-45, and > 45 years) and HIV status (positive or negative). A 10-year time horizon was used from the healthcare provider's perspective. The primary outcome was the incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) gained. One-way and probabilistic sensitivity analyses were performed to assess the robustness of the results. RESULTS: Modelled incidence rates of anal cancer and anogenital warts were significantly reduced following the implementation of 9vHPV vaccine strategies. Vaccinating all MSM aged ≥12 years prevented the most anogenital warts (52.5 %) and anal cancer cases (70.4 %). Across all MSM vaccination strategies assessed, the ICERs were below the willingness-to-pay (WTP) threshold of USD 50,696 per QALY gained (one-time Hong Kong GDP per capita) or cost-saving, indicating that all 9vHPV strategies were cost-effective. In probabilistic sensitivity analyses, the vaccination strategy for MSM aged ≥12 years consistently demonstrated a high probability of being cost-effective. Furthermore, when the cost of the 9vHPV vaccine decreased or the time horizon was extended, the ICERs for vaccinating MSM aged ≥12 years further declined, making the strategy more cost-effective. CONCLUSION: Our findings support the implementation of 9vHPV vaccination for MSM in Hong Kong, with vaccinating all MSM aged ≥12 years offering the greatest health and economic benefits.
引用
- You D, Quan J, Bishai D, et al. Evaluating cost-effectiveness of 9-valent HPV vaccination for men who have sex with men by HIV status in Hong Kong. Vaccine. 2025. PMID: 40848676. doi:10.1016/j.vaccine.2025.127625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。